End for PCOS? New name could change women’s healthcare

Health experts just redefined the futures of women suffering from the hormonal disorder Polycystic Ovary Syndrome, or PCOS. The condition recently received another name, redefining how it is perceived, diagnosed, and treated.

Researchers deemed the term “PCOS” inaccurate after years of clinical use, arguing that it overly emphasizes ovarian cysts while overlooking the broader hormonal and metabolic dysfunction involved. The updated classification was presented during the European Congress of Endocrinology in Prague and published in The Lancet, affecting a condition estimated to impact one in every eight women globally.

The new PMOS classification is expected to reshape clinical practice, with updated diagnostic criteria, expanded screening approaches, and improved recognition of metabolic, reproductive, psychological, and dermatological symptoms that were previously underdiagnosed under the PCOS framework.

“While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition,” stated Helene Teede, director of Monash University’s Monash Centre for Health Research & Implementation, who led the name change process.

According to researchers, the term “PCOS” implies the presence of pathological ovarian cysts. While this is present in some cases, the condition is not limited to cysts but is instead a broad multisystem disorder affecting endocrine, metabolic, reproductive, psychological, and dermatological systems.

For too long, detection and management have focused primarily on the ovaries and ‘cysts,’ contributing to missed diagnoses and inadequate treatment. As a result, an estimated 70% of women with PMOS worldwide remain unaware of their condition, according to the World Health Organization (WHO).

As the majority of cases are left undiagnosed, infertility remains a common complication, brought on by the untreated hormonal disorder along with the prevalence of weight gain, obesity, insulin resistance, diabetes, and cardiovascular disease.

According to WHO, irregular or absent periods, difficulty conceiving, excessive hair on the face or body, female-pattern baldness, weight gain, acne, or oily skin could signal the occurrence of the condition. With PMOS as a name, symptoms like these could be considered a warning sign of the hormonal disorder.

While the name change does not immediately change the existing treatment approach, it may now change how experts, patients, and even health advocates understand the condition.

It is an end for the PCOS term itself, but the hormonal disorder is yet to be eradicated. With revisions on how it is perceived, the future of women with PMOS is redefined for good.